留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会. 人乳头瘤病毒疫苗临床应用中国专家共识[J]. 协和医学杂志, 2021, 12(2): 189-201. doi: 10.12290/xhyxzz.2021-0082
引用本文: 中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会. 人乳头瘤病毒疫苗临床应用中国专家共识[J]. 协和医学杂志, 2021, 12(2): 189-201. doi: 10.12290/xhyxzz.2021-0082
Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. doi: 10.12290/xhyxzz.2021-0082
Citation: Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. doi: 10.12290/xhyxzz.2021-0082

人乳头瘤病毒疫苗临床应用中国专家共识

doi: 10.12290/xhyxzz.2021-0082
基金项目: 

国家自然科学基金重点项目 81630060

国家自然科学基金面上项目 81974410

妇幼健康研究会研究项目 2018AMCHS008

浙江省科技厅重点研发项目 2020C03025

上海市科学技术委员会科研计划项目 18411963600

详细信息

    通信作者: 马丁1, dma@tjh.tjmu.edu.cn, 魏丽惠2, weilhpku@163.com, 谢幸3, xiex@zju.edu.cn, 孔北华4, kongbeihua@sdu.edu.cn

  • 中图分类号: R271.1; R711.74

Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine

More Information
  • 摘要: 人乳头瘤病毒(human papilloma virus,HPV)疫苗接种是预防HPV感染及相关疾病的有效方法,是防控HPV感染相关疾病的一级预防措施。低龄人群接种效果优于高龄人群,性暴露前接种免疫效果最佳。HPV疫苗不仅适用于普通人群,同样推荐用于高危、特殊人群。对于具有遗传易感、高危生活方式和HIV感染的适龄女性优先推荐接种HPV疫苗。适龄女性无论是否存在HPV感染、细胞学是否异常均可接种HPV疫苗。近期有妊娠计划、妊娠期或哺乳期女性不宜接种HPV疫苗。接种HPV疫苗后仍应进行子宫颈癌筛查。
    利益冲突:  无
    通信作者: 马丁1, dma@tjh.tjmu.edu.cn, 魏丽惠2, weilhpku@163.com, 谢幸3, xiex@zju.edu.cn, 孔北华4, kongbeihua@sdu.edu.cn
  • 表  1  我国国家药品监督管理局批准上市的HPV疫苗特点和接种程序

    项目 国产双价HPV疫苗
    (大肠杆菌)
    双价HPV吸附疫苗 四价HPV疫苗 九价HPV疫苗
    全球上市时间 - 2007年 2006年 2014年
    中国上市时间 2019年 2016年 2017年 2018年#
    预防HPV型别 16/18 16/18 6/11/16/18 6/11/16/18/31/33/45/52/58
    中国女性适宜接种年龄 9~45岁 9~45岁 9~45岁& 16~26岁
    预防HPV感染相关
    疾病(中国批准)
    子宫颈癌、CIN 1级、CIN 2/3级、AIS,HPV 16/18持续性感染 子宫颈癌、CIN 1级、CIN 2/3级、AIS 子宫颈癌、CIN 1级、
    CIN 2/3级、AIS
    子宫颈癌、CIN 1级、CIN 2/3级、AIS,9种HPV相
    关亚型感染
    表达系统 大肠杆菌 杆状病毒 酿酒酵母 酿酒酵母
    免疫量 共接种3剂,每剂0.5 mL 共接种3剂,每剂0.5 mL 共接种3剂,每剂0.5 mL 共接种3剂,每剂0.5 mL
    接种方法和部位 肌内注射,首选上臂三角肌 肌内注射,首选上臂三角肌 肌内注射,首选上臂三角肌 肌内注射,首选上臂三角肌
    免疫程序(接种方案)* 第0、1、6个月,9~14岁
    接种2剂
    第0、1、6个月 第0、2、6个月 第0、2、6个月
    HPV:人乳头瘤病毒;CIN:子宫颈上皮内瘤变;AIS:原位腺癌;#2018年10月美国食品药品监督管理局批准九价HPV疫苗可用于9~45岁女性[38]& 2020年11月国家药品监督管理局批准四价HPV疫苗应用于9~19岁女性; *1年内接种3剂为完成免疫接种
    下载: 导出CSV

    表  2  普通和特殊人群(女性)HPV疫苗接种的推荐级别*#

    不同人群 推荐级别
    普通人群
      9~26岁女性 优先推荐
      27~45岁女性 推荐
    特殊人群
      HPV感染/细胞学异常的适龄女性 推荐
      妊娠期女性 不推荐
      哺乳期女性 谨慎推荐
      有HPV相关病变治疗史的适龄女性 推荐
      有遗传易感和子宫颈癌发病高危因素的适龄女性* 优先推荐
      免疫功能低下的适龄女性#
        HIV感染者 优先推荐
        自身免疫性疾病患者:系统性红斑狼疮、风湿性关节炎、结缔组织病、干燥综合征、桥本甲状腺炎等 推荐
        1型和2型糖尿病患者 推荐
        肾衰竭接受血液透析者 与临床医生共同探讨
        器官/骨髓移植术后长期服用免疫抑制剂者 与临床医生共同探讨
    HPV:同表 1;HIV:人类免疫缺陷病毒;*建议首次性暴露前或尽早接种;#全身脏器功能差、病情不乐观、预期寿命有限者,不推荐
    下载: 导出CSV
  • [1] McBride AA. Oncogenic human papillomaviruses[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372: 20160273. doi:  10.1098/rstb.2016.0273
    [2] Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States[J]. Sex Transm Dis, 2014, 41: 660-664. doi:  10.1097/OLQ.0000000000000193
    [3] Gargano J, Meites E, Watson M, et al. Manual for the Surveillance of Vaccine-Preventable Diseases: Human Papillomavirus[EB/OL]. (2020-04-28)[2020-11-28]. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html.
    [4] World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine, 2017, 35: 5753-5755. doi:  10.1016/j.vaccine.2017.05.069
    [5] Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings[J]. J Infect Dis, 2010, 202: 1789-1799. doi:  10.1086/657321
    [6] Guan P, Howell-Jones R, Li N, et al. Human papillo-mavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer[J]. Int J Cancer, 2012, 131: 2349-2359. doi:  10.1002/ijc.27485
    [7] World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017[J]. Wkly Epidemiol Rec, 2017, 92: 241-268. http://www.ncbi.nlm.nih.gov/pubmed/28596091
    [8] de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11: 1048-1056. doi:  10.1016/S1470-2045(10)70230-8
    [9] Wu EQ, Liu B, Cui JF, et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study[J]. Cancer Causes Control, 2013, 24: 795-803. doi:  10.1007/s10552-013-0162-8
    [10] Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18[J]. Cancer Causes Control, 2009, 20: 1705-1713. doi:  10.1007/s10552-009-9422-z
    [11] de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8: e180-e190. doi:  10.1016/S2214-109X(19)30488-7
    [12] de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer, 2017, 141: 664-670. doi:  10.1002/ijc.30716
    [13] Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World[R/OL]. (2019-06-17)[2020-11-25]. https://hpvcentre.net/statistics/reports/XWX.pdf?t=1606721151283.
    [14] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi:  10.3322/caac.21492
    [15] Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in China[R/OL]. (2019-06-17)[2020-11-25]. https://hpvcentre.net/statistics/reports/CHN.pdf?t=1606722464904.
    [16] Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papill-omavirus infection natural history, transmission and human papill-omavirus-related cancer incidence by gender and anatomic site of infection[J]. Int J Cancer, 2015, 136: 2752-2760. doi:  10.1002/ijc.29082
    [17] Centers for Disease Control and Prevertion. Human Papill-omavirus (HPV) Infection[EB/OL]. (2015-06-04)[2020-11-25]. https://www.cdc.gov/std/tg2015/hpv.htm.
    [18] Colombara DV, Wang SM. The impact of HPV vaccin-ation delays in China: lessons from HBV control programs[J]. Vaccine, 2013, 31: 4057-4059. doi:  10.1016/j.vaccine.2013.06.031
    [19] Zeng ZY, Yang HT, Li ZB, et al. Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51, 345 HPV Genotyping Results from China's Largest CAP Certified Laboratory[J]. J Cancer, 2016, 7: 1037-1043. doi:  10.7150/jca.14971
    [20] Wei LH, Xie X, Liu JH, et al. Efficacy of quadrivalent human papill-omavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37: 3617-3624. doi:  10.1016/j.vaccine.2018.08.009
    [21] Zhu FC, Li J, Hu YM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J]. Hum VaccinImmunother, 2014, 10: 1795-1806. doi:  10.4161/hv.28702
    [22] Li RC, Li YP, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females[J]. Vaccine, 2012, 30: 4284-4291. doi:  10.1016/j.vaccine.2012.02.079
    [23] Hu YM, Guo M, Li CG, et al. Immunogenicity nonin-feriority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Sci China Life Sci, 2020, 63: 582-591. doi:  10.1007/s11427-019-9547-7
    [24] Van Damme P, Meijer CJLM, Kieninger D, et al. A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J]. Vaccine, 2016, 34: 4205-4212. doi:  10.1016/j.vaccine.2016.06.056
    [25] Joura EA, Kyrgiou M, Bosch FX, et al. Human papillo-mavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy[J]. Eur J Cancer, 2019, 116: 21-26. doi:  10.1016/j.ejca.2019.04.032
    [26] Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women[J]. Am J Obstet Gynecol, 2008, 198: 261. e1-e11. doi:  10.1016/j.ajog.2007.09.001
    [27] Australian Government Department of Health. Human papillomavirus (HPV) immunization service[EB/OL]. (2019-09-26)[2020-11-25]. https://www.health.gov.au/health-topics/immunisation/immunisation-services/human-papillomavirus-hpv-immunisation.
    [28] Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J]. Hum Vaccin, 2009, 5: 696-704. doi:  10.4161/hv.5.10.9515
    [29] Zhu FC, Hu SY, Hong Y, et al. Efficacy, immuno-genicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase Ⅱ/Ⅲ, rando-mised, controlled trial[J]. Cancer Med, 2019, 8: 6195-6211. doi:  10.1002/cam4.2399
    [30] Qiao YL, Wu T, Li RC, et al. Efficacy, Safety, and Immuno-genicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial[J]. J Natl Cancer Inst, 2020, 112: 145-153. doi:  10.1093/jnci/djz074
    [31] Future Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J]. N Engl J Med, 2007, 356: 1915-1927. doi:  10.1056/NEJMoa061741
    [32] Lei JY, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer[J]. N Engl J Med, 2020, 383: 1340-1348. doi:  10.1056/NEJMoa1917338
    [33] Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372: 711-723. doi:  10.1056/NEJMoa1405044
    [34] Garland SM, Pitisuttithum P, Ngan HYS, et al. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries[J]. J Infect Dis, 2018, 218: 95-108. doi:  10.1093/infdis/jiy133
    [35] Ruiz-Sternberg ÁM, Moreira ED Jr, Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women[J]. Papillomavirus Res, 2018, 5: 63-74. doi:  10.1016/j.pvr.2017.12.004
    [36] International Federation of Gynecology & Obstetrics. Global Guidance For Cervical Cancer Prevention and Control (2009)[EB/OL]. [2020-11-25]. https://www.figo.org/sites/default/files/2020-07/Control_English_version.pdf.
    [37] 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识(简版)[J]. 中华预防医学杂志, 2019, 53: 1218-1235. doi:  10.3760/cma.j.issn.0253-9624.2019.12.006
    [38] U.S. Food & Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old[EB/OL]. (2018-10-05)[2020-11-25]. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old.
    [39] Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68: 698-702. doi:  10.15585/mmwr.mm6832a3
    [40] Centers for Disease Control and Prevertion. Vaccines at 11 to 12 Years[EB/OL]. (2020-02-25)[2020-11-25]. https://www.cdc.gov/vaccines/parents/by-age/years-11-12.html.
    [41] Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillo-mavirusVaccination[J]. Obstet Gynecol, 2017, 129: 1. doi:  10.1097/AOG.0000000000002052
    [42] Government of Canada. Human papillomavirus vaccine: Canadian Immunization Guide[EB/OL]. [2020-11-25]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html.
    [43] Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation[J]. CA Cancer J Clin, 2020, 70: 274-280. doi:  10.3322/caac.21616
    [44] Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vacci-nation in China[J]. Cancer Epidemiol, 2012, 36: 384-390. doi:  10.1016/j.canep.2012.01.009
    [45] Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China[J]. Cancer, 2019, 125: 1030-1037. doi:  10.1002/cncr.32003
    [46] Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies[J]. Int J Cancer, 2012, 131: 2929-2938. doi:  10.1002/ijc.27571
    [47] Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreac-tivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13: 324-327. doi:  10.1158/1055-9965.EPI-03-0166
    [48] Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age[J]. Br J Cancer, 2011, 105: 28-37. doi:  10.1038/bjc.2011.185
    [49] Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo popul-ation[J]. Gynecol Oncol, 2019, 154: 110-117. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiA3ZjA3MzY2MDI1YzU4MTUxMWRlYTE3MGYyZjczOTllNRoIZXlqamw2bGM%3D
    [50] Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J]. Lancet, 2017, 390: 2143-2159. doi:  10.1016/S0140-6736(17)31821-4
    [51] Panagiotou OA, Befano BL, Gonzalez P, et al. Effectof bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial[J]. BMJ, 2015, 351: h4358. http://smartsearch.nstl.gov.cn/paper_detail.html?id=f6423ef439caab48ed04eeb0a03b2b30
    [52] Angelo MG, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience[J]. Pharmacoepidemiol Drug Saf, 2014, 23: 456-465. doi:  10.1002/pds.3593
    [53] Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Morb Mortal Wkly Rep, 2010, 59: 626-629. http://www.cabdirect.org/abstracts/20103180825.html
    [54] Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papilloma virus type 6/11/16/18 vaccine: a combined analysis of five random-ized controlled trials[J]. Obstet Gynecol, 2009, 114: 1179-1188. doi:  10.1097/AOG.0b013e3181c2ca21
    [55] Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV Vaccination and the Risk of Adverse Pregn-ancyOutcomes[J]. N Engl J Med, 2017, 376: 1223-1233. doi:  10.1056/NEJMoa1612296
    [56] Landazabal CS, Moro PL, Lewis P, et al. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017[J]. Vaccine, 2019, 37: 1229-1234. doi:  10.1016/j.vaccine.2018.11.077
    [57] Tan J, Xiong YQ, He Q, et al. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of sponta-neous abortion: a systematic review and meta-analysis[J]. BMC Pregnancy Childbirth, 2019, 19: 302. doi:  10.1186/s12884-019-2425-1
    [58] Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2014, 63: 1-30.
    [59] Min KJ, Kwon SH, Kim K, et al. Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Onco-logy Guideline[J]. J Gynecol Oncol, 2019, 30: e31. doi:  10.3802/jgo.2019.30.e31
    [60] Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?[J]. Gynecol Oncol, 2013, 130: 264-268. doi:  10.1016/j.ygyno.2013.04.050
    [61] Garland SM, Paavonen J, Jaisamrarn U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccin-ation prevents recurrent high grade cervical intraep-ithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial[J]. Int J Cancer, 2016, 139: 2812-2826. doi:  10.1002/ijc.30391
    [62] Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2[J]. Gynecol Oncol, 2018, 151: 229-234. doi:  10.1016/j.ygyno.2018.08.033
    [63] Pieralli A, Bianchi C, Auzzi N, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J]. Arch Gynecol Obstet, 2018, 298: 1205-1210. doi:  10.1007/s00404-018-4926-y
    [64] Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study[J]. Clin Infect Dis, 2012, 54: 891-898. doi:  10.1093/cid/cir1036
    [65] Deshmukh AA, Chhatwal J, Chiao EY, et al. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intrae-pithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men[J]. Clin Infect Dis, 2015, 61: 1527-1535. doi:  10.1093/cid/civ628
    [66] Markowitz LE, Dunne EF, Saraiya M, et al. Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)[EB/OL]. (2014-08-29)[2020-11-25]. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm.
    [67] Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component?[J]. Int J Cancer, 1999, 82: 775-781. doi:  10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V
    [68] Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours[J]. Int J Cancer, 2000, 88: 698-701. doi:  10.1002/1097-0215(20001201)88:5<698::AID-IJC3>3.0.CO;2-J
    [69] Chen D, Juko-Pecirep I, Hammer J, et al. Genome-wide association study of susceptibility loci for cervical cancer[J]. J Natl Cancer Inst, 2013, 105: 624-633. doi:  10.1093/jnci/djt051
    [70] Shi YY, Li L, Hu ZB, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J]. Nat Genet, 2013, 45: 918-922. doi:  10.1038/ng.2687
    [71] Tovar JM, Bazaldua OV, Vargas L, et al. Human papillomavirus, cervical cancer, and the vaccines[J]. Postgrad Med, 2008, 120: 79-84. doi:  10.3810/pgm.2008.07.1794
    [72] Moscicki AB. Impact of HPV infection in adolescent populations[J]. J Adolesc Health, 2005, 37: S3-S9. http://www.ncbi.nlm.nih.gov/pubmed/16310138
    [73] Zhao FH, Forman MR, Belinson J, et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer, 2006, 118: 442-448. doi:  10.1002/ijc.21327
    [74] How CD4 Counts Help Treat HIV and AIDS[EB/OL]. (2019-06-23)[2020-11-26]. https://www.webmd.com/hiv-aids/cd4-count-what-does-it-mean.
    [75] Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study[J]. Vaccine, 2013, 31: 5745-5753. doi:  10.1016/j.vaccine.2013.09.032
    [76] Kojic EM, Kang M, Cespedes MS, et al. Immun-ogenicity and safety of the quadrivalent human papillo-mavirus vaccine in HIV-1-infected women[J]. Clin Infect Dis, 2014, 59: 127-135. doi:  10.1093/cid/ciu238
    [77] McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus[J]. Clin Infect Dis, 2019, 68: 788-794. doi:  10.1093/cid/ciy575
    [78] Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study[J]. Ann Rheum Dis, 2013, 72: 659-664. doi:  10.1136/annrheumdis-2012-201393
    [79] Nelson DR, Neu AM, Abraham A, et al. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD[J]. Clin J Am Soc Nephrol, 2016, 11: 776-784. doi:  10.2215/CJN.09690915
    [80] Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, et al. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD[J]. Nephrol Dial Transplant, 2017, 32: 132-136. http://smartsearch.nstl.gov.cn/paper_detail.html?id=be9b371a7a34532890f084946ddaa72c
    [81] Reinholdt K, Thomsen LT, Dehlendorff C, et al. Human papillomavirus-related anogenitalpremalignancies and cancer in renal transplant recipients: A Danish nationwide, registry-based cohort study[J]. Int J Cancer, 2020, 146: 2413-2422. doi:  10.1002/ijc.32565
    [82] Kumar D, Unger ER, Panicker G, et al. Immuno-genicity of quadrivalent human papillomavirus vaccine in organ trans-plant recipients[J]. Am J Transplant, 2013, 13: 2411-2417. doi:  10.1111/ajt.12329
    [83] CIOMS Working Groups. Guidelines for Preparing Core Clinical-Safety Information on Drugs[M/OL]. [2020-11-26]. https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS-Working-Group-Ⅲ-and-Ⅴ.pdf.
    [84] Reiter PL, Brewer NT, Gottlieb SL, et al. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen[J]. Vaccine, 2009, 27: 6840-6844. doi:  10.1016/j.vaccine.2009.09.016
    [85] Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years[J]. Hum Vaccin, 2009, 5: 705-719. doi:  10.4161/hv.5.10.9518
    [86] Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase Ⅲ randomized study of healthy women aged 18-45 years[J]. Hum Vaccin, 2011, 7: 1343-1358. doi:  10.4161/hv.7.12.18281
    [87] Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial[J]. Cancer Med, 2017, 6: 12-25. doi:  10.1002/cam4.869
    [88] Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J]. Vaccine, 2019, 37: 889-897. doi:  10.1016/j.vaccine.2018.12.030
    [89] Moreira ED Jr, Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase Ⅲ Clinical Trials[J]. Pediatrics, 2016, 138: e20154387. doi:  10.1542/peds.2015-4387
    [90] Lu B, Kumar A, Castellsagué X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis[J]. BMC Infect Dis, 2011, 11: 13. doi:  10.1186/1471-2334-11-13
    [91] Yih WK, Greene SK, Zichittella L, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females[J]. Vaccine, 2016, 34: 172-178. doi:  10.1016/j.vaccine.2015.09.087
    [92] Centers for Disease Control and Prevertion. HPV Vaccine Safety and Effectiveness Data[EB/OL]. (2019-11-15)[2020-11-26]. https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html.
  • 加载中
表(2)
计量
  • 文章访问数:  149
  • HTML全文浏览量:  5
  • PDF下载量:  53
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-22
  • 录用日期:  2021-01-22
  • 网络出版日期:  2021-02-01
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回